![](https://i0.wp.com/sitn.hms.harvard.edu/wp-content/uploads/2020/09/neuron.jpg?resize=870%2C773&ssl=1)
Slowing ALS with a Two-Drug Therapy
Results from a phase 2 clinical trial reveal that a new two-drug therapy for ALS can slow disease progression by six weeks over a six-month period. This therapy could possibly improve lifespan and quality of life, and may be effective in other neurodegenerative disorders as well. Continue reading Slowing ALS with a Two-Drug Therapy